Loading
Precision oncology pioneer who showed that matching drugs to each patient's mutations, in combination, improves outcomes.
Razelle Kurzrock (Medical College of Wisconsin; formerly MD Anderson and UC San Diego) built one of the first large precision oncology programmes and led the I-PREDICT trial, which showed that individualised combination therapy matched to a higher fraction of a tumour's alterations improves progression-free survival. She founded the WIN Consortium and the field's methodology for N-of-1 matching, and has led early-phase trials in rare and refractory cancers.
| Title | Journal | Year |
|---|---|---|
| Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study | Nature Medicine | 2019 |
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative | Clinical Cancer Research | 2012 |
Shares I-PREDICT, WINTHER, AI trial matching & clinical decision support, Comprehensive genomic profiling.
Shares Comprehensive genomic profiling and the tag precision-oncology.
Shares AI trial matching & clinical decision support, Comprehensive genomic profiling.
Shares AI trial matching & clinical decision support, Comprehensive genomic profiling.
Shares Master protocol (platform, basket and umbrella trials), AI trial matching & clinical decision support, Comprehensive genomic profiling.
Shares Master protocol (platform, basket and umbrella trials), Comprehensive genomic profiling.
Shares Master protocol (platform, basket and umbrella trials), AI trial matching & clinical decision support.
Shares Master protocol (platform, basket and umbrella trials), Comprehensive genomic profiling.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/